HealthStream (HSTM) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
13 Mar, 2026Executive summary
Achieved record quarterly and full-year 2025 revenues of $304.1 million, with Q4 revenue up 7.4% year-over-year and Adjusted EBITDA up 16.4%; full-year Adjusted EBITDA grew 7.5% to $71.8 million.
Completed acquisitions of Virsys12 and MissionCare Collective in Q4, expanding product offerings and career networks.
CEO contributed $3.8 million in stock for employee equity grants, resulting in a $3.5 million non-cash expense but no dilution to shareholders except the CEO.
Maintains leadership as the #1 workforce platform in U.S. healthcare, serving a rapidly growing and highly regulated industry.
Expanded product ecosystem and user base, including launch of new AI-driven applications.
Financial highlights
Q4 2025 revenues reached $79.7 million; full-year revenues were $304.1 million.
Q4 Adjusted EBITDA was $18.8 million, up 16.4%; full-year Adjusted EBITDA was $71.8 million.
Q4 net income was $2.5 million, down 48.1% due to a CEO stock grant; non-GAAP net income was $5.4 million, up 9.5%.
Cash and cash equivalents at year-end 2025 totaled $57 million, with no debt and a $50 million unused credit facility.
Free cash flow for the year was $31.1 million, up 5.5% year-over-year.
Outlook and guidance
2026 revenue guidance: $323–$330 million (6.2%–8.5% growth); net income: $20.4–$22.8 million; Adjusted EBITDA: $73–$77 million.
Capital expenditures expected between $31–$34 million; effective tax rate projected at 22%.
Inorganic revenue from acquisitions expected to be ~$13 million in 2026.
Guidance excludes impact from future acquisitions, dispositions, or asset impairments.
Latest events from HealthStream
- Q2 2024 revenue up 3.4% to $71.6M, guidance reaffirmed, and SaaS platform growth continues.HSTM
Q2 20243 Feb 2026 - Record Q3 revenue, profit growth, and raised guidance highlight strong operational momentum.HSTM
Q3 202419 Jan 2026 - Strong SaaS growth, acquisitions, and platform innovation drive robust 2024 results and 2025 outlook.HSTM
Q4 202423 Dec 2025 - 2025 proxy covers director elections, auditor ratification, executive pay, and ESG priorities.HSTM
Proxy Filing1 Dec 2025 - Annual meeting to address director elections, pay, and auditor ratification.HSTM
Proxy Filing1 Dec 2025 - Record Q2 2025 revenue, profit growth, and a $25M share buyback highlight strong results.HSTM
Q2 202523 Nov 2025 - Revenue up 1%, profit down 17%; guidance trimmed, but cash flow and bookings remain strong.HSTM
Q1 202519 Nov 2025 - Record Q3 revenue, strong cash, and strategic actions drive continued growth.HSTM
Q3 202513 Nov 2025